CR-31-B (-)
An inhibitor of viral translation.
General information
CR-31-B (-) is a potential anti-SARS-CoV-2 rocaglate drug, acting likely as an inhibitor of viral RNA translation (Müller et al., 2021).
CR-31-B (-) on PubChem
Synonyms
CR-1-31-B; (1R,2R,3S,3Ar,8bS)-1,8b-dihydroxy-N,6,8-trimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b]/aim/benzofuran-2-carboxamide
COC1=CC=C(C=C1)[C@]23[C@@H]([C@H]([C@H]([C@]2(C4=C(O3)C=C(C=C4OC)OC)O)O)C(=O)NOC)C5=CC=CC=C5
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo
Small molecule In vitro Mechanism |
Vero E6 cells; primary human bronchial epithelial cells | 4.10 | Inhibited SARS-CoV-2 replication in Vero E6 cells with EC50 of ca. 1.8 nM and reduced viral titres below detection threshold in primary human airway epithelial cells at 100 nM. It reduced viral protein accumulation and formation of replication/transcription complexes. |
Jan/08/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
|
Jan/08/2021 |
